Professor Rose has over 25 years’ experience in clinical R&D spanning the academic sector, working at the Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australia’s national science agency and in industry. Over his career he has worked closely with clinicians developing the next generation of molecular imaging and therapeutic platforms targeting oncology applications, neurodegenerative and brain development disorders. Before joining AdvanCell Isotopes, Professor Rose was Director of a CSIRO Future Science Platform driving innovation in the Medical Technologies and Pharmaceuticals sector, including the development of innovative diagnostic platforms and novel theranostics for improved delivery of radiopharmaceuticals for difficult to treat cancers. At AdvanCell Isotopes he is Head of Translational Medicine and Clinical Science and helps oversee the preclinical and clinical development of AdvanCell’s growing (Lead-212) 212Pb-based Targeted Alpha Therapy program.